Monica Gray

Monica has an undergraduate degree in Accounting and an MBA she earned - with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.
Atossa Genetics Inc. (NASDAQ:ATOS)

Atossa Genetics Inc. (NASDAQ:ATOS) Drops

Atossa Genetics Inc. (NASDAQ:ATOS)

Atossa Genetics Inc. (NASDAQ:ATOS) felt the wrath of Wall Street after announcing the pricing of a $5.1 million public offering of common stock. Shares of the clinical stage pharmaceutical company fell 46.9%, to end Thursday’s trading session at $0.45 a share.

Atossa Genetics Inc. (NASDAQ:ATOS)

Public Offering Reaction

The company has priced 11.5 million shares of common stock at a public offering price of $0.44 a share. Atossa Genetics Inc. (NASDAQ:ATOS) has also granted underwriters an overallotment option for the purchase of 1 million additional shares of common stock. Gross proceeds before deduction of underwriting discounts, commissions, and other estimated offering costs should be about $5.1 million.

Atossa Genetics Inc. (NASDAQ:ATOS) plans to use net proceeds from the offering for general corporate purposes. The offering should close on or about October 30, 2017.

The $5.1 million public offering appears to have spooked investors as the stock dropped from $1.50 a share to $0.45. Following the slump, the stock is now down by more than 40% for the year.

Oral Endoxifen Trials

The pricing of the public offering comes just days after the clinical stage pharmaceutical company announced preliminary results from its Phase 1 study of Oral Endoxifen. The company is investigating the drug for the treatment of recurrent breast cancer.

Trial results indicate that Endoxifen met all its objectives with no clinically significant safety signals or adverse events reported. Oral Endoxifen was also well tolerated at each dose levels. According to Atossa Genetics Inc. (NASDAQ:ATOS), the study results demonstrate the sustainability of oral Endoxifen for further clinical development.

“Based on these positive preliminary results, we are advancing our oral Endoxifen into Phase 2 studies,” commented Dr. Steven C. Quay, CEO, and President. “We expect our initial Phase 2 study will be in women who are refractory to Tamoxifen and we expect to begin that study in the first quarter of 2018,” continued Dr. Quay.

Estimates indicate that about 250,000 women will be diagnosed with breast cancer in the U.S this year with 40,000 expected to die. Breast cancer is the second leading cause of cancer death in the US. Atossa Genetics Inc. (NASDAQ:ATOS) estimates the potential market for its oral and tropical formulation of Endoxifen if approved at over $1 billion.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ATOS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Sierra Oncology Inc. (NASDAQ:SRRA)

Sierra Oncology Inc. (NASDAQ:SRRA) Continues Uptrend

Sierra Oncology Inc. (NASDAQ:SRRA)

Sierra Oncology Inc. (NASDAQ:SRRA) traded higher after announcing the appointment of Dr. Andrew Allen to its Board of Directors. The stock was up by 12.6% in Wednesday’s trading session to end the day at $2.14 a share.

Sierra Oncology Inc. (NASDAQ:SRRA)

Wednesday’s rally saw the stock break a key resistance level at $1.90, affirming a bullish run that began in June. The stock is now up by more than 30% for the year as it continues to trade in a strong uptrend marked by a new 52-week high of $2.20 a share.

The appointment of Dr. Allen comes at a time when the clinical stage drug development company is advancing next-generation DNA Damage Response therapies for the treatment of patients with cancer. He joins the company with vast experience, having served as the Chief Executive of Gristone Oncology, and as Chief Medical Officer at Pharmion Corporation.

“I’ve been highly encouraged by the sophisticated approach Sierra is taking to developing SRA737, leveraging the rich biology of Chk1 synthetic lethality to incorporate prospective genomic profiling strategies to enhance patient selection in their trials and potentially improve their prospects for positive outcomes. I look forward to working closely with this outstanding team,” said Dr. Allen.

SRA737 Development

Sierra Oncology Inc. (NASDAQ:SRRA) will report preclinical data supporting the development of SRA737 at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer on October 26-30, 2017. The candidate drug is currently being investigated in two Phase 1 clinical trials in patients with advanced cancer.

The Chk1 inhibitor, SRA737 has been granted a selection patent by the U.S Patent and Trademark Office, which extends coverage until 2033. A similar European patent was issued in February. According to Sierra Oncology, the intellectual property establishes a solid foundation for the potential future commercialization of the promising candidate drug

“We anticipate generating additional intellectual property claims as we advance our DDR-focused research activities and our innovative genetics-driven clinical programs,” said CEO Nick Glover.

Q2 Financial Results

Separately, Sierra Oncology Inc. (NASDAQ:SRRA) reported a net loss of (-$10.3) million for the three months ended June 30, 2017, down from a net loss of (-$12.9) million reported a year ago. Cash and cash equivalent as of the end of the quarter stood at $125 million compared to $109 million as of December 31, 2016. According to the clinical stage company, the existing cash is sufficient to fund operations through mid-2019.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $SRRA and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Quotient Ltd (NASDAQ:QTNT) Reports 99.8% Blood Grouping Concordance

Quotient Ltd (NASDAQ:QTNT)

Quotient Ltd (NASDAQ:QTNT) shares gained 11.9% after the diagnostics company reported positive concordance data from MosaiQ Verification and validation studies in blood grouping. According to the Chief Executive Officer, Paul Cowan, 99.8% blood grouping concordance demonstrates the robustness of MosaiQ as a diagnostics platform.

Quotient Ltd (NASDAQ:QTNT)

MosaiQ Platform Development

The positive study results mark an important milestone in the development of the highly informative and disruptive testing platform for transfusion diagnostics. Quotient Limited has also demonstrated feasibility of the platform with respect to detection of nucleic acids.

Over the next 12 months, Quotient Ltd (NASDAQ:QTNT) plans to carry out European field trials and then file for European regulatory approval. MosaiQ European commercialization has already began with the company expecting tender offers in FY2018.

Quotient Ltd (NASDAQ:QTNT) stock gapped higher on the news – touching highs of $5.52 a share before it dropped to end Wednesday’s trading session at $5.19.

Private Placement

In addition, Quotient Ltd (NASDAQ:QTNT) has entered into agreements with certain shareholders for the issuance of 7.9 million shares priced at $4.64 a share. The company has also issued 550,000 pre-funded warrants at $4.75 and exercisable for up to 550,000 ordinary shares, priced at $0.01 per ordinary share.

Quotient Ltd (NASDAQ:QTNT) expects aggregate proceeds of $40 million from the private placement. The company expects an additional $49 million on the exercise of 8.4 million warrants priced at $0.125 a warrant. Net proceeds from the offering are to be used to fund the ongoing development and commercial scale-up of MosaiQ and for working capital among other general corporate purposes. The offering should close on or about October 26, 2017.

“I am also pleased that we have strengthened our balance sheet through our recently announced private placement, which was led by a small group of existing shareholders, with participation by directors and management. This financing is an added vote of confidence for what we have achieved to date and what we have the potential to achieve in the future,” said Mr. Cowan.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $QTNT and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Viking Therapeutics Inc. (NASDAQ:VKTX)

Viking Therapeutics Inc. (NASDAQ:VKTX)’s VK2809 Succeeds in Trial

Viking Therapeutics Inc. (NASDAQ:VKTX)

Viking Therapeutics Inc. (NASDAQ:VKTX) fell 5.36% after announcing positive results from an eight-week study of VK2809 as a novel treatment for a wide range of lipid disorders. Study results demonstrate lipid-lowering effects of the small molecule thyroid receptor, as well as anti-fibrotic benefits.

Viking Therapeutics Inc. (NASDAQ:VKTX)

VK2809 vs. Lipid Disorders

Treatment with VK2809 shows statistically significant reductions in liver triglycerides, liver cholesterol, and total lipids in treated animals, relative to vehicle controls. The trials also showed significant changes in expression of key genes associated with non-alcoholic Steatohepatitis development and progression.

“The observed changes in gene expression are exciting, as they corroborate the histologic improvements and suggest potential benefits of insulin sensitivity and metabolic control. VK2809’s therapeutic and safety profile continue to suggest a promising potential role in settings such as NASH and hyperlipidemia,” said CEO, Brian Lian.

Viking Therapeutics Inc. (NASDAQ:VKTX) is trading in an uptrend despite the 5% drop. The stock is up by more than 100% for the year and outperforming the overall industry. Renewed investor interest follows positive clinical trials of the company’s lead program VK2809 and VK0214.

According to Viking Therapeutics Inc. (NASDAQ:VKTX), VK2809 was well tolerated with no significant changes to liver functions it to test subjects relative to controls. VK2809 is a small molecule thyroid receptor that promises therapeutic potential in a range of lipid disorders.

Clinical data has already demonstrated that treatment with VK2809 could lead to a significant reduction in plasma triglycerides as well as LDL Cholesterol in subjects with mild hypercholesterolemia. Viking Therapeutics is currently evaluating it in a randomized, double-blind, placebo-controlled parallels group Phase 2 study.

VK0214 Development

In addition to VK2809, Viking Therapeutics Inc. (NASDAQ:VKTX) is also evaluating VK0214 on the treatment of X-linked adrenoleukodystrophy. The U.S. Food and Drug Administration has already granted the thyroid receptor beta Orphan Drug status.

Study results from a 25-week proof-of-concept study showed VK0214 led to statistically significant reductions in Plasma levels of very long chain fatty acids in treated animals. The therapy also demonstrated reductions in long chain fatty acids in tissues such as in the liver, brain, and spinal cord.

“The impressive effects on plasma VLCFAs strengthen our belief that activation of the thyroid beta receptor can lead to improved lipid processing. The reduction in tissue VLCFAs is particularly exciting, as it suggests a potential direct benefit on tissue-related toxicities,” said Brian Lian, Ph.D., chief executive officer of Viking.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $VKTX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Pulmatrix Inc. (NASDAQ:PULM)

Pulmatrix Inc. (NASDAQ:PULM)’s PUR1900 Awarded Designation

Pulmatrix Inc. (NASDAQ:PULM)

Shares of Pulmatrix Inc. (NASDAQ:PULM) fell 4.86% in Tuesday’s trading session to end the day at $1.76 a share. The sell-off comes just days after the U.S. Food and Drug Administration (FDA) designated the clinical stage biopharmaceutical company’s candidate drug, Pulmazole (PUR1900), as a Qualified Infectious Disease Product (QIDP).

Pulmatrix Inc. (NASDAQ:PULM)

FDA Designation

The designation is designed to speed up the development of novel drugs that have the potential to address important pathogens. Pulmatrix stands to enjoy up to 5 years of market exclusivity should the drug succeed in clinical trials and gain regulatory approval.

The candidate drug has already achieved orphan drug designation for the treatment of fungal infections in the airways of patients with cystic fibrosis. The QIDP designation further expands PUR 1900 status to include Asthma patients

“This second QIDP designation is a significant boost to our efforts to make this drug available as quickly as possible to severe asthma patients suffering from fungal lung infections,” said Pulmatrix CEO Robert Clarke, PhD. “It will give us the benefit of an expedited regulatory review and significantly expands the potential population we can treat with our Pulmazole product.

Patent Protection Milestone

In addition to FDA designation milestones, Pulmatrix Inc. (NASDAQ:PULM) has received two important patents from the United States Patent and Trademark Office (USPTO). One of the patents expands the potential of the company’s technology for delivering drugs directly to the lungs.

The company has developed a dry powder that it claims can fly easily through the airways and deliver a wide range of types of drugs. The technology is designed to increase the efficiency of drug delivery while also reducing the side effects associated with existing approaches.

The second patent expands the patent protection of Pulmatrix Inc. (NASDAQ:PULM) candidate drug PURO200 for the treatment of chronic obstructive pulmonary disease. The new patent broadens the intellectual property protection so that it is no longer limited to specific characteristics and performance criteria.

“The new PUR0200 patent will make it more difficult for potential competitors to develop similar products or to work around our product candidate,” explained Robert W. Clarke, Ph.D., Chief Executive Officer for Pulmatrix. “The new claims also will make it possible for us to add in a second therapeutic to create a combination product.”

Pulmatrix Inc. (NASDAQ:PULM) is currently developing PUR0200 in Europe and the United States, following regulatory pathways that offer quickest approvals.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $PULM and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

OpGen Inc. (NASDAQ:OPGN)

OpGen Inc. (NASDAQ:OPGN) Awarded $860,000 CDC Contract

OpGen Inc. (NASDAQ:OPGN)

Shares of OpGen Inc.(NASDAQ:OPGN) fell 1.4% after the Center for Disease Control and Prevention awarded the company a contract for the development of clinical support tools for antimicrobial stewardship and infection control. The agency has since granted the company $860,000 for the development of a cloud-based mobile software which is to be used in low and middle-income countries.

OpGen Inc. (NASDAQ:OPGN)

CDC Contract Award

OpGen Inc. (NASDAQ:OPGN) is to work with Teqqa, LLC and Universidad El Bosque (UEB) of Bogota, Colombia led by Maria Virginia Villegas, M.D., M.Sc. to bring the solution to fruition. Teqqa is to provide a cloud and mobile based software platform to support antimicrobial stewardship.

The platform is to be used to identify patients that require infection control precautions and assist in the implementations of the necessary precautions. The software will be translated into Spanish to support WHONET data integration.

“OpGen looks forward to working with the CDC to help address this urgent global need,” stated Evan Jones, CEO of OpGen. “Improving antimicrobial stewardship worldwide has been identified by the CDC, the World Health Organization (WHO) and governments worldwide as a core activity in the fight to contain and manage infections from multidrug-resistant pathogens.”

OpGen Inc. (NASDAQ:OPGN) is also developing the Acuitas AMR Gene Panel u5.47, a PCR test designed to detect antibiotic resistance genes. The test can detect up to five bacterial pathogens in clinical isolate and urine specimens. It can also be used to detect up to 47 antimicrobial resistance genes.

According to OpGen’s senior vice president of research and development, Dr. Terry Walker, antimicrobial drug resistance is an urgent global health concern.

“Our data show that the Acuitas AMR Gene Panel accurately detects and quantitates key complicated urinary tract infection pathogens. We are encouraged by the development data for Acuitas Lighthouse Knowledgebase prediction algorithms currently in development,” said Dr. Walker.

OPGN Stock Performance

The CDC award did little to strengthen investor confidence in the precision medicine company. The stock has underperformed the overall industry, having shed more than 70% in market value since the start of the year.

OpGen Inc. (NASDAQ:OPGN) is currently trading in a downtrend as investors sentiments on the street continue to drop. However, the stock is currently rated as a ‘strong buy’ by two analyst firms according to data compiled by Zacks Investment Research.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $OPGN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

SenesTech Inc (NASDAQ:SNES) Gets Boost from Distribution Agreement

SenesTech Inc (NASDAQ:SNES)

SenesTech Inc (NASDAQ:SNES) stock is up over 75% in the first 1.5 hours of trading after the company announced a national distribution agreement with Univar. The thinly traded pest-control company typically trades less than 100,000 shares per day but one hour into today’s session over 420,000 shares have exchanged hands.

Shares of SenesTech Inc (NASDAQ:SNES)

Dr. Loretta P. Mayer, Chair, CEO and co-founder of SenesTech stated in a press release “Univar is an excellent sales and distribution partner for SenesTech, with their extensive breadth and depth of coverage, their direct connection with the pest control operators, and their commitment to sustainability. They will immediately provide us with nationwide sales coverage and nine dedicated sales representatives. As they have assured us, as our distributor, Univar sees their role as an active partner in creating and building a market for ContraPest.”

ContraPest is a liquid fertility control bait for rodents that targets the reproductive capacity of both male and female rats, rendering them infertile.

SNES Stock Review

Shares of SenesTech Inc (NASDAQ:SNES) recently touched $1.58 which established a new 52-week low. The 52-week high, $10.69, was established in early 2017. SNES shares are down over 80% year-to-date despite having sales that have increased from $200,000 in 2014 to $300,000 in 2016. Per share losses shrunk from (-$1.80) in 2015 to (-$1.08) for 2016. Additionally, the company has managed to keep the number of outstanding shares at the same level (10.13 million) for the last three years, thereby avoiding shareholder dilution that sometimes accompanies companies in rapid growth.

Analysts have given SNES shares a 1-year consensus price target of $14 according to the NASDAQ.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $SNES and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

DURECT Corporation (NASDAQ:DRRX) Sinks on Phase 3 Results

DURECT Corporation (NASDAQ:DRRX)

DURECT Corporation (NASDAQ:DRRX) shares cratered over 60% on Friday on a volume figure of over 8.6 million – DRRX stock previously had an average daily volume of just 456,000. Investors bailed on the biotechnology company after the biotechnology company announced that its drug candidate, Posimir failed to meet its primary efficacy endpoint of pain reduction in a statistical meaningful manner in the Phase 3 PERSIST study. The primary efficacy endpoint was a reduction in pain on movement over the first 48 hours after surgery as compared to standard bupivacaine HCl.

DURECT Corporation (NASDAQ:DRRX)

DRXX Share Action

DRRX stock ended Thursday at $1.97. Then, on Friday, DURECT Corporation (NASDAQ:DRRX) shares gapped down to open at $0.84. Throughout the day the stock tried to breech and sustain the $1 level. However DRXX closed at $0.78 – only $0.04 above the 52-week low of $0.74 established back in May. Since that low, the shares had been on a clear uptrend and traded just under $2.20 the two days prior to the crash.

Sandoz Deal

DURECT Corporation (NASDAQ:DRRX) and Sandoz AG (“Sandoz”) entered into a license agreement to develop and market POSIMIR in the United States, and the agreement became effective in June 2017. DURECT retains commercialization rights in the rest of the world. Under terms of the agreement, Sandoz made an upfront payment of $20 million, with the potential for up to an additional $43 million in milestone payments based on successful development and regulatory milestones, and up to an additional $230 million in sales-based milestones. DURECT is responsible for the completion of the ongoing PERSIST Phase 3 clinical trial for POSIMIR as well as FDA interactions through approval. DURECT Corporation (NASDAQ:DRRX) also has certain manufacturing obligations under this agreement.
DURECT Corporation (NASDAQ:DRRX) posted a profit of ($0.16) per share in 2012. Since then, losses have been posted every year and in 2016 they posted their largest loss of (-$0.18) per share. In 2016 the company also their lowest sales figure of 14 million. Currently, two analyst have a “Hold rating on DRXX shares and one has the stock rated at a “Buy”.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $DRRX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Digital Ally, Inc. (NASDAQ:DGLY)

Digital Ally, Inc. (NASDAQ:DGLY) Rockets on Open!

Digital Ally, Inc. (NASDAQ:DGLY)

Digital Ally, Inc. (NASDAQ:DGLY) stock gapped up to open the trading day on news that The Safariland Group announced a newly formed partnership with Digital Ally® for an exclusive distribution agreement of Digital Ally’s VuLink® car based auto-activation system. Twenty minutes into trading, DGLY shares have traded 2.4 million shares versus the listed daily average of just 47,300 – or 500 times the average!

digital ally, DGLY

Stan Ross, CEO of Digital Ally, Inc. (NASDAQ:DGLY) “We are pleased that others are recognizing the importance and value of our products and intellectual properties, especially our patented VuLink auto-activation technology. We are excited to partner with VIEVU to give them the products and technology they need to bring this capability to VIEVU’s customers.”

VuLink System

The Digital Ally VuLink system wirelessly sends a signal to automatically activate the user’s body-worn camera based on various actions with the vehicle, such as a siren being activated, lights being turned on, or a door opening. The VuLink system, when connected to the VIEVU body-worn camera can improve consistency in camera activation by automatically turning on the officer’s camera based on agency-selected vehicle triggers. The automatic activation will significantly reduce situations where body-worn camera footage is not available because an the user forgot to activate the camera.

DGLY Stock Action

Digital Ally, Inc. (NASDAQ:DGLY) stock trade near $6 in February before beginning a long, consistent slide that saw the shares touch their 52-week low of $2.15. Yesterday DLGY shares closed at $2.20 then opened today at $3.05 on the news detailed above. The inter-day high, so far, of $3.50 was hit in the first ten minutes and then the sellers stepped in.

Prior to today’s price action, DGLY shares have been underperforming for investors. They have been down over 47% year-to-date and lost 20% in the past month alone. Despite the poor performance over 2017, two analysts have a “Strong Buy” on DGLY stock with a consensus price target of $8.50.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $DGLY and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Immune Design Corp (NASDAQ:IMDZ) Awarded Orphan Drug Designation

Immune Design Corp (NASDAQ:IMDZ)

Immune Design Corp (NASDAQ:IMDZ) shares fell 16% after the clinical stage company announced that the European Medicine Agency had granted its immunotherapy, G100, for non-Hodgkin’s lymphoma Orphan Drug Designation. The EMA designation is normally assigned to products targeting the treatment of rare medical conditions with prevalence of not more than 5 in 10,000 people.

The designation accords Immune Design Corp (NASDAQ:IMDZ) a string of benefits not limited to reduced fees for regulatory activities. The company also stands to enjoy protocol assistance when it comes to clinical trials. In addition, the clinical stage immunotherapy company will be granted 10 years of market exclusivity upon approval by regulators in the Union.

The company’s lead drug for the treatment of non-Hodgkin’s lymphoma has also been granted Orphan Drug Designation in the U.S by the Food and Drug Administration. Developed from Immune Design Corp (NASDAQ:IMDZ)’s GLAAS discovery platform, the candidate product is designed to activate innate and adaptive immunity in the tumor microenvironment.

IMDZ Stock Performance

Immune Design Corp (NASDAQ:IMDZ)

Immune Design Corp (NASDAQ:IMDZ) free fall in the market shows no signs of slowing down as the stock has shed more than 40% in market value since the start of the month. The stock is currently trading at levels last seen at the start of the year.

Declining investor’s sentiments on the stock follows reports that the company plans to initiate a Phase 3 study of cancer vaccine candidate CMB305 in NY-ESO-1. The timing of the study, slated for mid-2018, appears to have spooked investors. The stock has also been downgraded by analysts at Wells Fargo to a ‘Neutral’ – seen as another cause for alarm among investors.

Immune Design Pipeline

CMB305 is one of Immune Design primary candidates currently in multiple clinical trials in patients with soft tissue sarcoma. The product is being investigated as a monotherapy and in combination with Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY)’s RHHBY Tecentriq.

“The trial will have progression-free survival (PFS) followed by overall survival (OS) as co-primary endpoints. If the PFS endpoint is successful, the FDA offered that it may support full approval of CMB305. Depending on the rate of events, final PFS analysis may occur as early as 24 months from the first patient dosed,” Immune Design in a statement.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $IMDZ and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.